ABCELLERA BIOLOGICS INC

ABCLNASDAQ

🏆 #1448 by market capEarnings Nov 4US Equity

$512.27▲ $6.76 (+1.32%)

Simulated price

🔔

Track ABCL

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 1.3%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$4.25B

Small Cap

📈Revenue Growth (YoY)

+160.6%

High Growth

📊Gross Margin

75.0%

High

💵FCF Margin

-271.2%

Thin

⚖️P/S Ratio

64.2x

Expensive

Otter Score

Fair

No chart data available for ABCL.

Trading Snapshot

Day Range: $507.97 – $521.75
52-Week Range: $2.75 – $14.23
Volume: $1.80B
Avg Volume: $1.97B
Shares Outstanding: 305.4M
Next Earnings: Dec 7, 2026

Fundamentals Snapshot

Annual Revenue: $75M
Last Q Revenue: $4M
P/E Ratio: -25.8
P/S Ratio: 64.2x
EPS (TTM): $-0.54
Dividend Yield: 0.00%

Why Investors Own ABCL

✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
✓Healthy economics — 34% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABCELLERA BIOLOGICS INC

ABCL

Financial Trends

Revenue (TTM)

$75M▲ +0.9% YoY

Gross Margin (TTM)

34.4%▲ +4.5% YoY

Operating Income (TTM)

$10M▲ +0.9% YoY

Free Cash Flow (TTM)

$5M▲ +0.9% YoY

StockOtter · stockotter.space

About ABCELLERA BIOLOGICS INC

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

🦦